Climb Bio (CLYM) AI Stock Analysis

• Market Cap: $270.01M
• Dividend Yield: N/A
• Average Volume (3M): 721.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: 64.81%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 68,184,430
• 10 Day Avg. Volume: 1,217,427
• 30 Day Avg. Volume: 721,779
• PEG Ratio: -0.07
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.57
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 6.80
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $10.50
• Price Target Upside: 165.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $4.00 ▲(1.01% Upside)

Overall score reflects a solid balance sheet and improving technical trend as key positives, offset by pre-revenue losses with worsening cash burn and limited valuation support (negative P/E, no dividend). Corporate events are supportive on clinical progress but tempered by legal/payment uncertainty.

Positive Factors

Low leverage balance sheet

A conservatively levered balance sheet with negligible debt reduces refinancing and interest-rate risk, preserving financial flexibility to fund clinical programs. This supports multi-year R&D execution and lowers the chance that capital markets conditions will disrupt development timelines.

Cash runway into 2028

A multi-year cash runway materially reduces near-term financing pressure, allowing the company to pursue multiple clinical readouts and regulatory activities. This durable runway increases the likelihood of generating value from data before needing dilutive capital, supporting strategic optionality.

Diversified clinical-stage pipeline

Multiple ongoing trials across autoimmune and renal indications plus an in-licensed anti-APRIL program broaden the probability of clinical success. Geographic expansion (China IND clearance) and multiple near-term readouts create durable R&D optionality and reduce reliance on a single asset.

Negative Factors

High cash burn

Significant, worsening cash burn means development relies on continued external funding. Sustained negative free cash flow converts accounting losses into real cash depletion, increasing dilution risk if trials extend, costs rise, or anticipated milestones/funding do not materialize.

Pre-revenue, negative profitability

As a pre-commercial biotech with persistent losses, the company lacks operational revenue to offset R&D and G&A. Long-term viability depends on clinical success or external funding; absent product commercialization, profitability and return metrics will remain negative for an extended period.

Potential large contingent liability from dispute

An ongoing contractual dispute over milestone and royalty obligations could impose a material cash obligation if resolved against the company. Such an outcome would shrink the runway, force reprioritization of programs, and introduce structural uncertainty around past asset acquisitions.

Climb Bio Business Overview & Revenue Model

Company Description

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

How the Company Makes Money

Climb Bio Financial Statement Overview

Summary

Climb Bio is in its development phase, with significant R&D expenses and no revenue. The company has strong equity and cash reserves providing stability, but negative income and cash flow indicate challenges in achieving profitability without successful product development.

Income Statement

Climb Bio has experienced consistent losses with no revenue generation, typical for a biotechnology company in development stages. The company's EBIT and EBITDA margins are negative, reflecting ongoing operational expenses without offsetting revenue. The net income is consistently negative, highlighting significant operational challenges.

Balance Sheet

Climb Bio maintains a strong equity position with low debt, as indicated by a low debt-to-equity ratio. The company has substantial cash reserves, enhancing its financial stability. However, the lack of revenue generation and continuous accumulation of losses could impact long-term sustainability if not addressed.

Cash Flow

The company has negative operating and free cash flows, which are expected for a biotech firm without commercial products. The free cash flow has not shown growth, and reliance on financing activities is evident. This indicates potential cash burn risks if external funding sources diminish.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-38.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-55.42M	-30.36M	-40.27M	-45.13M	-35.67M	-11.77M
Net Income	-50.75M	-73.90M	-35.12M	-45.24M	-47.48M	-20.67M
Balance Sheet
Total Assets	182.30M	217.19M	110.47M	134.99M	173.24M	24.63M
Cash, Cash Equivalents and Short-Term Investments	86.90M	150.92M	106.80M	123.57M	136.48M	20.49M
Total Debt	580.00K	532.00K	349.00K	480.00K	0.00	0.00
Total Liabilities	5.30M	5.31M	2.87M	6.28M	6.04M	3.06M
Stockholders Equity	177.00M	211.88M	107.60M	128.72M	167.20M	21.57M
Cash Flow
Free Cash Flow	-44.43M	-15.56M	-20.60M	-37.37M	-36.07M	-14.10M
Operating Cash Flow	-44.24M	-15.56M	-20.60M	-37.37M	-36.07M	-14.10M
Investing Cash Flow	-76.11M	-121.09M	68.98M	34.44M	-114.97M	8.08M
Financing Cash Flow	41.00K	130.73M	841.00K	0.00	177.23M	4.92M

Climb Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Neutral. The current price of 3.96 is below the 20-day moving average (MA) of 4.35, above the 50-day MA of 2.92, and above the 200-day MA of 1.94, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 46.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLYM.

Climb Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLYM	60 Neutral	$270.01M	-5.27	-25.65%	―	―	64.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OVID	51 Neutral	$117.50M	-3.23	-60.06%	―	946.61%	-11.30%
HURA	46 Neutral	$45.95M	-1.16	-418.06%	―	―	99.21%
CGTX	44 Neutral	$125.35M	-2.99	-109.73%	―	―	50.39%
AGEN	41 Neutral	$159.16M	-2.20	―	―	-33.41%	81.19%
TVGN	41 Neutral	$63.16M	-1.78	―	―	―	-234.46%

Climb Bio Corporate Events

Climb Bio outlines 2026 clinical milestones and cash runway

On January 8, 2026, Climb Bio announced that during 2025 it initiated multiple clinical trials across its two lead antibody programs, including first-patient dosing in the PrisMN Phase 2 trial of budoprutug in primary membranous nephropathy in November 2025, ongoing Phase 1b/2a dosing in immune thrombocytopenia and a global Phase 1b trial in systemic lupus erythematosus, clearance in December 2025 to start a parallel SLE trial in China that will also enroll lupus nephritis patients, and completion of first-cohort dosing for both a subcutaneous formulation of budoprutug and its newly in-licensed anti‑APRIL antibody CLYM116 in healthy volunteers. The company highlighted a “data-rich” 2026, with initial readouts expected across all ongoing budoprutug and CLYM116 studies, alongside refreshed guidance that its cash, cash equivalents and marketable securities are expected to fund operations into 2028, positioning Climb Bio to advance its diversified autoimmune and renal disease portfolio while it expands leadership and board capabilities and deepens its global clinical and regulatory footprint, including through its collaboration with Beijing Mabworks in China.

The most recent analyst rating on (CLYM) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.

Climb Bio Challenges Alumis Milestone and Royalty Obligations

On December 31, 2025, Climb Bio, Inc. filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary Acelyrin, Inc., seeking a declaratory judgment over payment obligations tied to a January 11, 2024 Asset Purchase Agreement under which Climb’s subsidiary Tenet Medicines acquired budoprutug-related assets from Acelyrin. Climb contends that no “Royalty-Bearing Patents” were ever transferred or filed within the defined period under the agreement, meaning its budoprutug program does not meet the contract’s definition of a “Product” and therefore does not trigger milestone payments, including a $3 million milestone Alumis has invoiced for January 1, 2026 following Climb’s first Phase 2 patient dosing on November 17, 2025. The lawsuit underscores a significant contractual and financial dispute that could determine whether Climb owes up to roughly $100 million in additional earn-outs for a drug it says it is advancing without any patent protection contributed by Alumis or Acelyrin, with implications for Climb’s future cash commitments and for how similar biotech asset purchase structures are interpreted when key intellectual property is absent.

The most recent analyst rating on (CLYM) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.

Climb Bio Enters Exchange Agreement with RA Capital

On December 11, 2025, Climb Bio, Inc. entered into an exchange agreement with RA Capital Management and its affiliate, wherein 20,440,000 shares of Climb Bio’s common stock were exchanged for a pre-funded warrant to purchase an equivalent number of shares. This transaction, which is exempt from registration under the Securities Act, will result in RA Capital and its affiliates holding approximately 23% of the company’s voting power. The agreement includes provisions to prevent RA Capital from exceeding 33% ownership of the company’s stock, ensuring a balanced voting power among shareholders.

The most recent analyst rating on (CLYM) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.

Climb Bio Releases New Clinical Data on Budoprutug

Climb Bio, Inc. announced on October 17, 2025, the publication of new long-term follow-up clinical data for budoprutug, a novel anti-CD19 monoclonal antibody in development for B-cell mediated diseases. The data from a Phase 1b clinical trial showed that budoprutug provided long-term control of proteinuria in primary membranous nephropathy patients for up to three years, with no need for further immunosuppressive treatment in most cases and no severe treatment-related adverse events observed.

The most recent analyst rating on (CLYM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.